Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis.

  • sponsor
    Sun Pharma
Updated on 4 May 2022


This study is for adults, 18 or older with a clinical diagnosis of chronic moderate to severe plaque-type psoriasis that has been present for at least 6 months. Subjects must also have moderate to severe psoriasis of the nails at the screening and baseline visits and who are considered candidates for systemic therapy.


The study duration is approximately 15 visits over 72 weeks, not including the screening period. The study drug is given by subcutaneous (injection).

Condition Psoriasis and Psoriatic Disorders
Clinical Study IdentifierTX298614
SponsorSun Pharma
Last Modified on4 May 2022


Yes No Not Sure

Inclusion Criteria

years or older at the Screening visit
Subjects with a clinical diagnosis of chronic moderate to severe plaque-type psoriasis for at least 6 months with nail psoriasis
Willing to be given the study drug by injection
Willing to use contraception during the study
Meet additional study criteria to qualify

Exclusion Criteria

Subjects with any previous use of tildrakizumab or other IL-23/Th-17 pathway inhibitors, including p40, p19 and IL-17 antagonists for psoriasis
Prior use of TNF-alpha inhibitors with a wash-out period of 12 weeks would be allowed
Subjects with erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced, or medication-exacerbated psoriasis, or new-onset guttate psoriasis
History of alcohol or substance abuse within 6 months prior to Day 1 that in the opinion of the investigator will preclude participation in the study
Subjects with known history of HIV, Hepatitis B or Hepatitis C
Subjects with ongoing inflammatory skin diseases other than psoriasis or any other disease affecting the fingernails (fungal infection), which may potentially confound the evaluation of study treatment
Women of childbearing potential who are pregnant, intend to become pregnant (within 6 months of completing the study), or are lactating
Meet additional study criteria to qualify
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note